Live Virus Neutralisation of the 501Y.V1 and 501Y.V2 SARS-CoV-2 Variants following INO-4800 Vaccination of Ferrets

Frontiers in Immunology

Seshadri S. Vasan¹  Kate E. Broderick¹  Alexander J. McAuley²  Peter A. Durr²  Kim R. Blasdell²  Sarah Goldie²  Shane Riddell²  Mary Tachedjian²  Michael J. Kuiper³  Trevor R. F. Smith⁴  Julian D. Druce⁵ 

[1] Development Centre, Inovio Pharmaceuticals, San Diego, CA, United States;Commonwealth Scientific and Industrial Research Organisation, Australian Centre for Disease Preparedness, Geelong, VIC, Australia;Commonwealth Scientific and Industrial Research Organisation, Data61, Docklands, VIC, Australia;;Research &Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital and The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia;

关键词: biomolecular modelling;    COVID-19;    DNA vaccine;    neutralisation;    SARS-CoV-2 antibodies;    variants;   

DOI  :  10.3389/fimmu.2021.694857

来源: DOAJ

【 摘 要 】

The ongoing COVID-19 pandemic has resulted in significant global morbidity and mortality on a scale similar to the influenza pandemic of 1918. Over the course of the last few months, a number of SARS-CoV-2 variants have been identified against which vaccine-induced immune responses may be less effective. These “variants-of-concern” have garnered significant attention in the media, with discussion around their impact on the future of the pandemic and the ability of leading COVID-19 vaccines to protect against them effectively. To address concerns about emerging SARS-CoV-2 variants affecting vaccine-induced immunity, we investigated the neutralisation of representative ‘G614’, ‘501Y.V1’ and ‘501Y.V2’ virus isolates using sera from ferrets that had received prime-boost doses of the DNA vaccine, INO-4800. Neutralisation titres against G614 and 501Y.V1 were comparable, but titres against the 501Y.V2 variant were approximately 4-fold lower, similar to results reported with other nucleic acid vaccines and supported by in silico biomolecular modelling. The results confirm that the vaccine-induced neutralising antibodies generated by INO-4800 remain effective against current variants-of-concern, albeit with lower neutralisation titres against 501Y.V2 similar to other leading nucleic acid-based vaccines.

【 授权许可】

Unknown